A short neoepitope peptide (Nes2LR) converted into immunogenic nanoparticles prevented and eradicated renal cell carcinoma in mice at ultra-low doses, synergizing with immune checkpoint therapy.
Ultra-low dose eradicationThe neoepitope nanoparticle vaccine eradicated tumors at doses orders of magnitude lower than other vaccine adjuvants — a dramatic improvement in potency
What the researchers found
Single neoepitope Nes2LR as short peptide nanoparticle vaccine prevented tumor growth and eradicated disease in subcutaneous, lung metastasis, and orthotopic renal carcinoma models at doses orders of magnitude lower than other adjuvants. Synergized with checkpoint blockade.
Why it matters
Most neoepitope vaccines require complex long peptides or mRNA delivery. This shows that simple short peptides converted to nanoparticles can achieve powerful anti-tumor immunity at ultra-low doses — potentially making cancer vaccines simpler and cheaper.
The numbers in context
20 candidates; 1 functional (Nes2LR); worked in 20/60-plex; orders of magnitude lower dose; eradicated tumors in 3 models; synergized with checkpoint blockade
How the study worked
Preclinical study. RENCA murine renal carcinoma. 20 MHC-I neoepitopes predicted by sequencing. Screened as immunogenic nanoparticles. Nes2LR tested in subcutaneous, experimental lung metastasis, and orthotopic tumor models. Combination with immune checkpoint blockade.
Who was studied
BALB/c mice with RENCA renal adenocarcinoma (subcutaneous, lung metastasis, orthotopic)
What this study cannot tell us
Mouse renal carcinoma model — human tumors are more heterogeneous. Only 1 of 20 predicted neoepitopes was functionally active. Human MHC diversity makes neoepitope prediction more challenging. No human clinical data.
How to read the evidence
Moderate evidence: comprehensive preclinical study with 3 tumor models and combination therapy, but mouse model only with no human data.
When this study was published
Published 2021. Neoepitope cancer vaccines and peptide nanoparticle delivery are rapidly advancing toward human clinical trials.
The bigger picture
Converting short peptides into nanoparticles is a scalable, cost-effective vaccine platform. The success with multivalent (20-60 peptide) particles suggests real-world personalized cancer vaccines could include many neoepitopes simultaneously without losing potency.
Questions still open
- Can this nanoparticle platform identify functional human neoepitopes as efficiently?
- Would combination with anti-PD-1 plus neoepitope vaccine become a standard renal cancer approach?
- How quickly can personalized neoepitope nanoparticle vaccines be manufactured for individual patients?
Common questions
What is a neoepitope vaccine?
Why are nanoparticles important for this vaccine?
Read the original research
Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model.
Journal for immunotherapy of cancer, 9(12)
Citation
He, Xuedan; Zhou, Shiqi; Dolan, Melissa; Shi, Yuhao; Wang, Jianxin; Quinn, Breandan; Jahagirdar, Dushyant; Huang, Wei-Chiao; Tsuji, Moriya; Pili, Roberto; Ito, Fumito; Ortega, Joaquin; Abrams, Scott I; Ebos, John M L; Lovell, Jonathan F. (2021). Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model.. Journal for immunotherapy of cancer, 9(12). https://doi.org/10.1136/jitc-2021-003101